Bart A. Van De Wiel
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 23, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 05, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.
Journal: Communications medicine
Published: January 31, 2025
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 23, 2025
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 10, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Journal: The New England journal of medicine
Published: June 03, 2024
The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes.
Journal: Journal of clinical pathology
Published: December 12, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Journal: Nature medicine
Published: May 16, 2023
The limited value of sentinel lymph node biopsy in lentigo maligna melanoma: A nomogram based on the results of 29 years of the nationwide dutch pathology registry (PALGA).
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: May 08, 2023
Last Updated: 09/26/2026